Clinton Puts the Heat on Biotechs; Biogen Inc (BIIB) Slides

Weekly options are hot on Weekly options are hot on Biogen Inc (NASDAQ:BIIB), amid Clinton backlash

Sep 21, 2015 at 2:34 PM
facebook twitter linkedin

An article in The New York Times about the dramatic rise in prescription drug costs prompted Democratic presidential candidate Hillary Clinton to take to Twitter in response. Specifically, Clinton tweeted:
Clinton's comments have put pressure on the biotech sector amid a generally upbeat day on the Street. One such name feeling the heat is Biogen Inc (NASDAQ:BIIB), which was last seen down 6% at $295.68, bringing its year-to-date deficit to nearly 13%.

In the options pits, overall volume has jumped to 1.8 times what's typically seen at this point in the day, with speculators split on the equity's near-term trajectory. Specifically, three of BIIB's top five options reside in the weekly 9/25 series, and buy-to-open activity has been detected at the 305-strike call, as well as the 295- and 300-strike puts.

For those initiating new long call positions, the goal is for BIIB to reclaim its foothold north of the $300 mark by week's end, when the series expires. The put buyers, however, expect the stock to settle south of the respective strikes when the closing bell rings on Friday. Regardless of where the equity finishes the week, though, the most either set of options buyers has risked is the initial cash outlay.

Widening the sentiment scope reveals BIIB's options pits have been dominated by call buyers in recent weeks. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the security's 10-day call/put volume ratio of 1.54 ranks in the 75th percentile of its annual range, meaning calls have been bought to open over puts at a faster-than-usual clip.

Echoing this is the equity's Schaeffer's put/call open interest ratio (SOIR) of 0.92. Not only does this indicate call open interest outweighs put open interest among options expiring in three months or less, but it ranks lower than 87% of all similar readings taken in the past year. Simply stated, speculative traders are more call-heavy than usual toward BIIB.

Good news for those purchasing Biogen Inc's (NASDAQ:BIIB) near-term options: the stock's Schaeffer's Volatility Index (SVI) of 35% sits in the 30th percentile of its annual range. In other words, premium on the equity's short-term options is pricing in relatively low volatility expectations at the moment.

Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!